Biotech Bulls: Arrowhead Research Corp. (NASDAQ:ARWR), Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM), Zynerba Pharmaceuticals (NASDAQ:ZYNE), Intrexon Corporation (NYSE:XON)

Arrowhead Research Corp. (NASDAQ:ARWR) reported net loss for the three months ended June 30, 2015 was $15.9 million, or $0.27 per share based on 59.5 million weighted average shares outstanding. This compares with a net loss of $11.6 million, or $0.22 per share based on 51.9 million weighted average shares outstanding, for the three months ended June 30, 2014.Arrowhead Research Corp. (NASDAQ:ARWR) belongs to Healthcare sector. Its weekly performance is 9.46%. On last trading day company shares ended up $6.77. Arrowhead Research Corp. (NASDAQ:ARWR) distance from 50-day simple moving average (SMA50) is 1.77%.

On 30 July, Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) announced that $20,970,000 of its 5.0% Convertible Senior Notes due 2020 (the “2020 Notes”) maturing February 15, 2020 have been converted into shares of common stock of the Company. Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) shares increased 14.67% in last trading session and ended the day at $14.62. ITEK return on assets is -80.10%. Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) quarterly performance is 148.22%.

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) announced that it has issued a letter to shareholders providing an update on the progress it has made to advance its two drug candidates, Iomab-B and Actimab-A, towards commercialization. On 05 August, Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) shares increased 5.85% and was closed at $1.81. Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) year to date (YTD) performance is -69.27%.

Zynerba Pharmaceuticals, Inc., (NASDAQ: ZYNE) announced the pricing of its initial public offering of 3 million shares of common stock at a public offering price of $14.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Zynerba. Zynerba Pharmaceuticals (NASDAQ:ZYNE) ended the last trading day at $16.25.

Intrexon Corporation (NYSE:XON) announced it will release first half and second quarter 2015 financial results after the market closes on Monday, August 10th, 2015. The Company will host a conference call at 5:30 PM ET to discuss the results and provide a general business update. Intrexon Corporation (NYSE:XON) shares increased 5.16% in last trading session and ended the day at $68.71. XON Gross Margin is 46.40% and its return on assets is -9.70%. Intrexon Corporation (NYSE:XON) quarterly performance is 73.60%.

Leave a Reply

Your email address will not be published. Required fields are marked *